메뉴 건너뛰기
Experimental Neurology
Volumn 144, Issue 1, 1997, Pages 2-3
Parkinson's disease: The case for novel treatment strategies
Author keywords

[No Author keywords available]
Indexed keywords

NEUROPROTECTIVE AGENT;
EID: 0031104813     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1996.6378     Document Type: Article
Times cited : (3)
References (8)
  • 1
    • 0014208039 scopus 로고
    • Aromatic amino acids and modification of parkinsonism
    • 1. COTZIAS, G. C., M. H. VANWOERT, AND L. M. SCHIFFER. 1967. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 2767: 374-379.
    • (1967) N. Engl. J. Med. , vol.2767 , pp. 374-379
    • Cotzias, G.C.1    Vanwoert, M.H.2    Schiffer, L.M.3
  • 2
    • 0029838423 scopus 로고    scopus 로고
    • Prospects for gene therapy in Parkinson's disease
    • 2. FREESE, A., M. STERN, M. G. KAPLITT, et al. 1996. Prospects for gene therapy in Parkinson's disease. Mov. Disord. 11(5): 469-488.
    • (1996) Mov. Disord. , vol.11 , Issue.5 , pp. 469-488
    • Freese, A.1    Stern, M.2    Kaplitt, M.G.3
  • 3
    • 0001925175 scopus 로고
    • Fluctuations of disability in Parkinson's disease: Clinical aspects
    • C. D. Marsden and S. Fahn, Eds., Butterworths, London
    • 3. MARSDEN, C. D., J. D. PARKES, AND N. QUINN. 1982. Fluctuations of disability in Parkinson's disease: Clinical aspects. Pages 96-122 in C. D. Marsden and S. Fahn, Eds., Movement Disorders. Butterworths, London.
    • (1982) Movement Disorders , pp. 96-122
    • Marsden, C.D.1    Parkes, J.D.2    Quinn, N.3
  • 4
    • 0029883235 scopus 로고    scopus 로고
    • The response to levodopa in Parkinson's disease: Imposing pharmacologic law and order
    • 4. NUTT, J. G., AND N. H. G. HOLFORD. 1996. The response to levodopa in Parkinson's disease: Imposing pharmacologic law and order. Ann. Neurol. 39: 561-573.
    • (1996) Ann. Neurol. , vol.39 , pp. 561-573
    • Nutt, J.G.1    Holford, N.H.G.2
  • 5
    • 0024456653 scopus 로고
    • Effect of deprenyl on the progression of disability in early Parkinson's disease
    • 5. PARKINSON STUDY GROUP. 1989. Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321: 1364-1371.
    • (1989) N. Engl. J. Med. , vol.321 , pp. 1364-1371
  • 6
    • 9044226896 scopus 로고    scopus 로고
    • Impact of deprenyl and tocopherol treatment in Parkinson's disease in DATATOP subjects requiring levodopa
    • 6. PARKINSON STUDY GROUP. 1996. Impact of deprenyl and tocopherol treatment in Parkinson's disease in DATATOP subjects requiring levodopa. Ann. Neurol. 39: 37-45.
    • (1996) Ann. Neurol. , vol.39 , pp. 37-45
  • 7
    • 0029895288 scopus 로고    scopus 로고
    • A double-blind pharmacokinetic and clinical dose-response study of entacapone as adjuvant to levodopa therapy in advanced Parkinson's disease
    • 7. RUOTTINEN, H. M., AND U. K. RINNE. 1996. A double-blind pharmacokinetic and clinical dose-response study of entacapone as adjuvant to levodopa therapy in advanced Parkinson's disease. Clin. Neuropharmacol. 19(4): 283-296.
    • (1996) Clin. Neuropharmacol. , vol.19 , Issue.4 , pp. 283-296
    • Ruottinen, H.M.1    Rinne, U.K.2
  • 8
    • 0011160816 scopus 로고
    • Symptomatic improvement without clinical fluctuations: Success markers and future success objectives
    • M. B. Stern, Ed., Wells Medical, Kent, UK
    • 8. STOCCHI, F. 1994. Symptomatic improvement without clinical fluctuations: Success markers and future success objectives. Pages 49-52 in M. B. Stern, Ed., Beyond the Decade of the Brain. Wells Medical, Kent, UK.
    • (1994) Beyond the Decade of the Brain , pp. 49-52
    • Stocchi, F.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.